Table 5.
CMAP compounds that reversed signature 2
| Rank | Drug | Condition (Reference) | Classification/Use |
|---|---|---|---|
| 6076 | Amodiaquine | Bronchoconstriction (15) | Antimalarial |
| 6077 | Sulfachlorpyridazine | Sulfonamide | |
| 6078 | Trichostatin A | Hyperresponsiveness (3) | Histone deacetylase inhibitor |
| 6079 | Lisuride | Anti-Parkinson reagent | |
| 6080 | Mephenytoin | Anticonvulsant | |
| 6081 | Nalbuphine | Opioid antagonist | |
| 6082 | Acetylsalicylsalicylic acid | Asthma* (87) | Aspirin impurity |
| 6083 | Tamoxifen | Asthma (67) | Estrogen receptor blocker |
| 6084 | Pioglitazone | Asthma (55) | PPAR agonist |
| 6085 | Trichostatin A | Hyperresponsiveness (3) | Histone deacetylase inhibitor |
| 6086 | Valproic acid | Hyperresponsiveness (68) | Anticonvulsant |
| 6087 | Bromperidol | Neuroleptic | |
| 6088 | Lomustine | Chemotherapy | |
| 6089 | Midecamycin | Antibiotic | |
| 6090 | Prestwick-664 | Unknown | |
| 6091 | Convolamine | Sensory nerve blocker | |
| 6092 | Trichostatin A | Hyperresponsiveness (3) | Histone deacetylase inhibitor |
| 6093 | Cotinine | Alkaloid | |
| 6094 | Berberine | Bronchoconstriction (71) | Alkaloid |
| 6095 | Trichostatin A | Hyperresponsiveness (3) | Histone deacetylase inhibitor |
| 6096 | Naftopidil | Alpha adrenergic blocker | |
| 6097 | Mianserin | Bronchoconstriction (43) | Antidepressant |
| 6098 | Valproic acid | Hyperresponsiveness (68) | Anticonvulsant |
| 6099 | Tretinoin | Hyperresponsiveness (49) | All-trans retinoic acid |
| 6100 | Trichostatin A | Hyperresponsiveness (3) | Histone deacetylase inhibitor |
Rank is order of correlation. CMAP, connectivity map; PPAR, peroxisome proliferator-activated receptor.
*
Adverse effect.